01:12 PM EDT, 06/06/2024 (MT Newswires) -- Replimune Group ( REPL ) shares jumped 25% in recent Thursday trading after follow-up analysis from a clinical trial showed a third of anti-PD1 failed melanoma patients receiving the company's RP1 plus nivolumab responded to treatment, improving on earlier data with all responses lasting greater than six months from baseline.

"With these data in hand, we are preparing for a commercial launch next year," Replimune ( REPL ) Chief Executive Officer Sushil Patel said in a statement.

The company plans to file a biologics license application for the drug in H2.

Replimune ( REPL ) is also planning to enroll patients in a confirmatory trial of the medicine starting Q3.

Price: 6.96, Change: +1.40, Percent Change: +25.14